Stock Taper
Genenta Science S.p.A. is an Italy-based clinical-stage biotech developing hematopoietic stem cell gene therapies, including Temferon for glioblastoma and other solid tumors.

Temferon™ is a first-in-class hematopoietic stem cell gene therapy targeting solid tumors by delivering immune-therapeutic payloads within the tumor microenvironment, currently in clinical trials for glioblastoma and metastatic renal cell carcinoma.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
IPSC | $2.02 | COMPARE |
TELO | $1.14 | COMPARE |
INMB | $2.33 | COMPARE |
SER | $2.46 | COMPARE |
BRNS | $0.75 | COMPARE |
SKYE | $1.77 | COMPARE |
MDCX | $0.26 | COMPARE |
JUNS | $4.18 | COMPARE |